Drug resistance forms the basis of the failure of most solid tumours to respond to chemotherapy (Curt et al., 1984; Goldie & Coldman, 1984) . Nevertheless, resistance is relatively exceptional in the normal dividing cell population and their continued sensitivity limits the administration of chemotherapeutic agents (Goldie & Coldman, 1984) .
It has recently been shown that some anticancer agents inhibit DNA synthesis in normal cells, but not in the resistant neoplastic cells (Bagshawe et al., 1987) . If this were so then it might be feasible to temporarily arrest the division of the normal cells and selectively introduce into neoplastic cells, that are in the S-phase, nucleotide analogues which possess either cell killing potential or are suitable for scintigraphy (Bagshawe, 1986) .
5-iodo-2-deoxyuridine (IUdR) is a synthetic analogue which competes with thymidine for phosphorylation and subsequent incorporation into newly formed DNA (Prusoff, 1959; Sneider & Potter, 1969) . Non-selective uptake of IUdR into normal cells precludes its effective use as a systemic agent (Kinsella et al., 1985) . Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which arrests DNA synthesis reversibly and synchronises cells at the G,/S interphase of the cell cycle (Tubiana et al., 1975) .
Experimental work conducted by our group (Bagshawe et al., 1987) (Prusoff, 1963) and reduction of the thymidine pool (Tattersall & Harrap, 1973 '31I-IUdR was prepared from 2-deoxyuridine (Sigma, Poole, UK) and Na'31', IBS30 (Amersham, UK) by an established method (Keough & Hofer, 1977) with only minor modifications. Specific activities of the order of 6 mCi mg' were obtained.
HU was administered orally in a dose of 2.0 g twice weekly 2-3 weeks prior to '31'-IUdR administration in order to encourage the neoplastic cells to develop resistance to it. The thyroid was blocked with potassium iodide, 120 mg three times a day for 7 days starting 24 h before the radiolabelled IUdR was given. Potassium perchlorate, 200 mg thrice daily was commenced 12 h prior to '3'I-IUdR to reduce secretion of '3'I into the stomach and continued for a total of 4 days. 5FU (200 mg m-2) was given intravenously as a bolus followed 30 min later by sequential intravenous injections of 5FU (600 mgm2) and HU (3.0gmm-2). Ten minutes later 5-15 mCi of '3'I-IUdR were administered intravenously over 10min.
Planar imaging was obtained 24 and 48 h after the administration of the '3'I-IUdR using an IGE Gemini gamma camera. Overall, 35% of the documented lesions revealed uptake (Table I) . Of the 26 patients investigated, 13 (50%) showed evidence of uptake by at least one disease site (Table  II) . No significant bone marrow toxicity (WHO grade > 3) followed this regimen as determined by a full blood count performed 2-3 weeks following the treatment. Three out of four previously documented brain lesions showed marked uptake of radioactivity. No uptake was demonstrated at previously unknown sites except for the patient with leiomyosarcoma in which uptake was shown at a subcutaneous site. In most patients there was a significant uptake by the spine and the stomach. Uptake was also noted in the breasts in three patients free from any breast pathology. There was no obvious correlation between dose of radioactivity administered and positive definition of tumours and similar images were obtained at 24 and 48 h after "1'I-labelled IUdR administration.
This pilot study explores the uptake of "311-labelled IUdR by neoplasms in vivo. Intra-abdominal deposits could have been overshadowed by the relatively high radioactivity retained in the spine and the stomach in many of the cases. Cerebral lesions on the other hand were well detected probably due to lack of rapidly proliferating cells in adjacent tissues.
Some lesions may have been missed simply because their DNA synthesis was suppressed by HU along with that of the host. Also, the pre-treatment with HU may have been inadequate to induce resistance to the drug by the tumour cells. Variations in the identification of tumours at various sites, if not merely determined by tumour size and vascularity (Brammer et al., 1979) , could be due to differences in cell kinetics. It is possible that some tumour cells in vivo are protected either by poor blood flow or by minimal dependence on exogenous thymidine pathways from incorporating '1I-IUdR and may even tend to arrest temporarily in response to the 5FU induced suppression of de novo thymidine formation. Despite this low sensitivity, specificity appears to be high and unlike other targeted isotope imaging techniques there is no significant non-specific retention of radioactivity in blood, liver or lungs.
This pilot study demonstrates that a significant proportion of human tumours demonstrate detectable uptake of 131-IUdR. Scheduling of drug administration was based on the pre-clinical studies in animal xenografts although further investigation should include biochemical and cell kinetic analysis of tumours and normal cells for evidence of sensitivity. Findings of this study warrant further detailed and controlled studies to explore the relation between the pharmacokinetics of drugs and tissue kinetics in vivo. Such studies may provide the basis for manipulating the regulatory balances that will determine the selective uptake of IUdR into tumour cells. If this were achieved, it would have implications for the incorporation of radiolabelled IUdR with therapeutic benefit. 
